BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30515868)

  • 41. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer.
    Kurokawa Y; Matsuura N; Kimura Y; Adachi S; Fujita J; Imamura H; Kobayashi K; Yokoyama Y; Shaker MN; Takiguchi S; Mori M; Doki Y
    Gastric Cancer; 2015 Oct; 18(4):691-7. PubMed ID: 25224659
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH.
    Casterá C; Bernet L
    Ann Diagn Pathol; 2020 Apr; 45():151451. PubMed ID: 31955049
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.
    Peiró G; Aranda FI; Adrover E; Niveiro M; Alenda C; Payá A; Seguí J
    Hum Pathol; 2007 Jan; 38(1):26-34. PubMed ID: 17056098
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of HER2 and its association with AP-2 in breast cancer.
    Pellikainen J; Naukkarinen A; Ropponen K; Rummukainen J; Kataja V; Kellokoski J; Eskelinen M; Kosma VM
    Eur J Cancer; 2004 Jul; 40(10):1485-95. PubMed ID: 15196531
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proposal to distinguish HER2-low from HER2-normal breast cancer by in situ hybridisation.
    Chen YY; Yang CF; Hsu CY
    J Clin Pathol; 2023 Nov; 76(11):753-756. PubMed ID: 37852628
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Concordance of HER2 Immunohistochemistry and Fluorescence
    Furrer D; Jacob S; Caron C; Sanschagrin F; Provencher L; Diorio C
    Anticancer Res; 2017 Jun; 37(6):3323-3329. PubMed ID: 28551685
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Establishing a Predictive Model to Predict Survival of de Novo Metastatic HER2-Low Breast Cancer: A National Cancer Database Analysis.
    Li M; Liu M; Zhu L; Lu H; Mao A; Liu H; Yu K; Dong L
    Discov Med; 2023 Jun; 35(176):283-292. PubMed ID: 37272095
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.
    Al-Saad S; Al-Shibli K; Donnem T; Andersen S; Bremnes RM; Busund LT
    J Thorac Oncol; 2010 Oct; 5(10):1536-43. PubMed ID: 20802349
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up.
    Jensen KC; Turbin DA; Leung S; Miller MA; Johnson K; Norris B; Hastie T; McKinney S; Nielsen TO; Huntsman DG; Gilks CB; West RB
    Breast Cancer Res Treat; 2008 Dec; 112(3):453-9. PubMed ID: 18193353
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.
    Yardley DA; Kaufman PA; Huang W; Krekow L; Savin M; Lawler WE; Zrada S; Starr A; Einhorn H; Schwartzberg LS; Adams JW; Lie Y; Paquet AC; Sperinde J; Haddad M; Anderson S; Brigino M; Pesano R; Bates MP; Weidler J; Bosserman L
    Breast Cancer Res; 2015 Mar; 17(1):41. PubMed ID: 25886996
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?
    Schindlbeck C; Janni W; Shabani N; Kornmeier A; Rack B; Rjosk D; Gerber B; Braun S; Sommer H; Friese K
    J Cancer Res Clin Oncol; 2005 Aug; 131(8):539-46. PubMed ID: 15887027
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Practical application of non-contact alternating current electric field mixing for reagent-saving in situ hybridisation of HER2.
    Kurihara N; Imai K; Nanjo H; Nakamura R; Wakamatsu Y; Akagami K; Terata K; Wakita A; Sato Y; Motoyama S; Akagami Y; Minamiya Y
    J Clin Pathol; 2019 Sep; 72(9):603-608. PubMed ID: 31129615
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The assessment of HER2 status in breast cancer: the past, the present, and the future.
    Nitta H; Kelly BD; Allred C; Jewell S; Banks P; Dennis E; Grogan TM
    Pathol Int; 2016 Jun; 66(6):313-24. PubMed ID: 27061008
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Institutional quality assurance for breast cancer HER2 immunohistochemical testing: identification of outlier results and impact of simultaneous fluorescence in situ hybridization cotesting.
    Green IF; Zynger DL
    Hum Pathol; 2015 Dec; 46(12):1842-9. PubMed ID: 26412217
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast.
    Li Z; Liu Q; Piao J; Hua F; Wang J; Jin G; Lin Z; Zhang Y
    BMC Cancer; 2016 Aug; 16(1):681. PubMed ID: 27562113
    [TBL] [Abstract][Full Text] [Related]  

  • 57. "HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH" Answer to the statistical issue to avoid misinterpretation.
    Casterá Redal C; Bernet Vegué L
    Ann Diagn Pathol; 2020 Oct; 48():151566. PubMed ID: 32763505
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer.
    Schlüter B; Gerhards R; Strumberg D; Voigtmann R
    J Cancer Res Clin Oncol; 2010 Sep; 136(9):1389-400. PubMed ID: 20217132
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer.
    Dandachi N; Dietze O; Hauser-Kronberger C
    Anticancer Res; 2004; 24(4):2401-6. PubMed ID: 15330190
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Decreased expression of stomatin predicts poor prognosis in HER2-positive breast cancer.
    Chen CY; Yang CY; Chen YC; Shih CW; Lo SS; Lin CH
    BMC Cancer; 2016 Aug; 16(1):697. PubMed ID: 27577936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.